Scientists in Germany claim to have made a breakthrough in developing a nasal Covid-19 vaccine that can neutralize the virus before it infects the body's upper airways. The new approach is based on creating a weakened but live form of the coronavirus, which stimulates the immune system to produce sterilizing immunity against future infections.
In animal studies, the vaccine showed remarkable promise, with two doses blocking the virus from copying itself in hamsters and achieving "sterilizing immunity" that prevented illness. However, more tests are needed before this vaccine can be widely used.
Researchers say that nasal vaccines offer an attractive solution to boost mucosal immunity - the immune defense that lines the upper airways where the virus enters the body. By targeting this area, the vaccine can prevent the virus from taking hold, reducing the risk of severe illness and transmission.
The new approach is not a new idea but rather a reimagining of an old concept. Scientists have been exploring ways to weaken viruses using techniques like codon pair deoptimization, which makes it harder for cells to translate the viral genetic material.
While the results from animal studies are encouraging, caution is warranted. More research, including human trials, is needed to confirm the vaccine's safety and efficacy. Additionally, concerns about respiratory infections being tough targets for inhaled vaccines mean that further testing will be necessary.
Other nasal Covid-19 vaccines are already in various stages of development, with some nearing completion of clinical trials. The global community needs a pan-coronavirus vaccine that can induce mucosal immunity and provide long-lasting protection.
Despite the challenges ahead, experts remain hopeful that this new approach holds promise for preventing future waves of infection. As one researcher noted, "It's not foolish to develop a vaccine that induces mucosal immunity and is long-lived."
In animal studies, the vaccine showed remarkable promise, with two doses blocking the virus from copying itself in hamsters and achieving "sterilizing immunity" that prevented illness. However, more tests are needed before this vaccine can be widely used.
Researchers say that nasal vaccines offer an attractive solution to boost mucosal immunity - the immune defense that lines the upper airways where the virus enters the body. By targeting this area, the vaccine can prevent the virus from taking hold, reducing the risk of severe illness and transmission.
The new approach is not a new idea but rather a reimagining of an old concept. Scientists have been exploring ways to weaken viruses using techniques like codon pair deoptimization, which makes it harder for cells to translate the viral genetic material.
While the results from animal studies are encouraging, caution is warranted. More research, including human trials, is needed to confirm the vaccine's safety and efficacy. Additionally, concerns about respiratory infections being tough targets for inhaled vaccines mean that further testing will be necessary.
Other nasal Covid-19 vaccines are already in various stages of development, with some nearing completion of clinical trials. The global community needs a pan-coronavirus vaccine that can induce mucosal immunity and provide long-lasting protection.
Despite the challenges ahead, experts remain hopeful that this new approach holds promise for preventing future waves of infection. As one researcher noted, "It's not foolish to develop a vaccine that induces mucosal immunity and is long-lived."